| | | | |

Sickest Mesothelioma Patients May Benefit Most from P/D Surgery

Patients with the worst cases of malignant pleural mesothelioma may stand to gain the most from pleurectomy and decortication (P/D) surgery.

That is the conclusion of researchers at the University of Chicago and Loyola University who subjected 114 mesothelioma patients to a quality of life and overall health scoring system both before and after P/D surgery.  

Considering Mesothelioma Surgery

The decision on whether or not to undergo mesothelioma surgery and which type of surgery to have is always a difficult one.

P/D surgery is extensive and involves the removal of the diseased pleural lining around the lungs, all or part of the diaphragm, and other at-risk tissues. Although it has been shown to slow the progression of mesothelioma, P/D, like any major surgery, also has the potential to negatively impact health-related quality of life.

But in a new study published in the World Journal of Surgery, the University of Chicago researchers say P/D surgery may be more worth the risk for some patients than for others. Ironically, it may be the sickest mesothelioma patients who see the most benefit.

Mesothelioma Surgery Study Design

To assess the impact of surgery on their quality of life, mesothelioma patients completed surveys and health assessments at baseline (prior to surgery) and at 1, 4-5, 7-8, and 10-11 months after surgery.

As expected, patients with a good performance status (a measure of overall health), those with the epithelioid variety of mesothelioma, and those whose tumors were relatively small had the fewest symptoms prior to surgery.

These patients reported feeling worse in the first month after surgery than they did before it, although their health gradually improved over time.

But for patients with the even-more-virulent non-epithelioid varieties of mesothelioma and those with large tumors, the opposite was true.

“Non-epithelioid histology and patients with large pathological tumor volume demonstrated greater improvement in global health, function and symptoms domains following pleurectomy with decortication,” writes internationally-known cardiothoracic surgeon and lead researcher, Wickii Vigneswaran, MD, of Loyola University Medical Center.

These two groups of mesothelioma patients also continued to see the greatest improvement in their overall health and quality of life in the months following surgery.

More Support for P/D Mesothelioma Surgery

Earlier this year, a team of researchers with Hofstra and Mount Sinai Universities in New York concluded that, regardless of mesothelioma type, P/D was the surgical approach most likely to result in improved quality of life.

That study analyzed 15 articles including 523 patients to compare P/D to the more radical lung-removing EPP surgery. They concluded that quality of life should be “strongly considered” when choosing a surgical approach for mesothelioma.

According to the researchers, about 22 percent of malignant pleural mesothelioma patients undergo some type of surgery, which has also been found to be an independent predictor of extended mesothelioma survival.

Sources:

Vigneswaran, WT, et al, “Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma”, September 25, 2017, World Journal of Surgery, Epub ahead of print

Schwartz, R, et al, “The impact of surgical approach on quality of life for pleural malignant mesothelioma, June 2017, Annals of Translational Medicine, pp. 230

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…